基于腺病毒载体的RSV和带状疹疫苗候选人的临床前开发
Lawrence Petherbridge1, Charlotte Davis1, Angela Robinson1
1Vaccitech Ltd., Harwell OX11 0DF, UK.
Vaccines
|November 25, 2023
概括
使用黑猩猩腺病毒载体的新组合疫苗候选者显示出保护老年人免受呼吸道同胞病毒 (RSV) 和带状疹的承诺. 用小鼠和棉鼠进行的研究证明了其免疫性和有效性,为潜在的双重保护铺平了道路.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 呼吸道同胞病毒 (RSV) 和带状疹 (由疹病毒引起,VZV) 对老年人构成重大健康风险.
- 目前的疫苗单独针对RSV和VZV,强调了联合免疫策略的必要性.
- 在老年人中,RSV感染可能导致严重疾病和死亡,而VZV的重新激活会导致痛苦的带状疹.
研究的目的:
- 评估新型黑猩猩腺病毒 (ChAd) 载体组合疫苗候选人针对RSV和带状疹的免疫性和有效性.
- 评估单一疫苗在老年人群中对这些常见的病毒感染提供双重保护的潜力.
主要方法:
- 开发基于ChAd的候选疫苗,其中包括RSV和VZV的抗原.
- 使用T细胞和抗体测定在小鼠模型中评估细胞和幽默免疫性.
- 通过在棉花大鼠中进行RSV挑战研究来评估疫苗的疗效.
主要成果:
- 候选疫苗在小鼠中表现出强大的细胞和幽默免疫反应.
- 与首选的ChAd-vectored疫苗候选人相同的原始增强疗法在棉花大鼠中显示出对RSV挑战的保护性有效性.
- 该研究证实了针对这些病毒性疾病的联合疫苗方法的可行性.
结论:
- 黑猩猩腺病毒载体是开发针对RSV和带状疹的有效组合疫苗的可行平台.
- 评估的RSV/结合疫苗候选药物显示,在老年人中具有双重保护的潜力.
- 进一步开发这种联合疫苗可以为弱势群体提供简化和有益的免疫战略.
相关概念视频
Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...


